Analysis of the WT1-VEGF molecular pathway in Acute Myeloid Leukaemia

Nikita Patel* 101463780 Bsc Genetics n.patel@ncl.ac.uk  Supervisor: Dr. Colin Miles  c.g.miles@ncl.ac.uk

Introduction:
WT1 regulates VEGF in blood development [Figure 1]. WT1 mutations and altered VEGF predict poor outcome in AML [Reference 1 & 2].

In kidney cells, WT1 is part of a molecular pathway including Sprk1 [Reference 3].

Figure 1: Absence of WT1 (WT1 null) severely reduces blood development from mouse embryonic stem (ES) cells. Graph shows the number of blood progenitor cell colonies (~2%) that derived from wild type ES cells and that addition of VEGF protein to the culture can partly restore blood development in WT1 null ES cells. This result highlights the importance of the WT1-VEGF pathway in blood development. [Thomas Cunningham, PhD Thesis, Newcastle University]

Aims:
• To find relative levels of VEGF and Sprk1 in AML samples
• To assess if changes in levels correlated with WT1 mutations
• To analyse AML samples for evidence of novel WT1 mutations

Results and Methods:
Testing oligonucleotide primers for RT-PCR using human podocyte cDNA and AML patient cDNA alongside a water blank. VEGF 4/1, 8/2, VEGFxxxb and Sprk1 oligos were selected for the remaining analyses.

Following KTS checking, the mutant WT1 samples were checked to ensure they included exon 9 splicing. This was done using the same method previously mentioned. The results showed that splicing had occurred in the samples, the sequence to look for was found by looking up the wild-type WT1 sequence and manually combining the sequences from exon 8 and exon 10. The spliced sequence was determined by using BLAST data available online, by determining the exons (coding sequences) from exon 8 and exon 10 through BLAST the sequences were found to be missing the intron (non-coding regions) it was possible to find where the sequences for exons 8 and 10 would join together, The samples did show the spliced sequence and so we are able to confirm the presence of exon 9 splicing in some AMLs (Figure 6.)

The sample suggest a single amino acid change at position 82 from an C to an A. This would convert from a CAC to CAA—changing the amino acid from a histidine to a glycine. This change could have a possible role in the worsened prognosis of WT1 exon 9 spliced AMLs. However this would need further investigation—capillary gel electrophoresis could be used to further single out the fragment to allow for re-sequencing to confirm a change which could be moved forward with.

Conclusions:
One of the samples -1706 shows a possible variation from the wild type sequence, a C to A conversion at position 82. 1706 shows normal levels of sprk1 and vegfxxxb. Although other samples show more variation in levels of Sprk1 and Vegfxxxb they do not show any variation from the wild type sequence. This could be further explored and may possibly have an affect on the prognosis of WT1 exon 9 spliced AMLs—If shown to have a regulatory effect this could be biochemically manipulated to return normal function to the pathway and increase chances of a better prognosis.

REFERENCES

Figure 2: This figure shows the results of an initial PCR reaction to determine if the oligos worked with the AML samples by comparing with a human podocyte cDNA sample known to express the genes of interest. The products were run on a 2% agarose gel and visualised with GelRed and UV light. Sprk1 and VEGFxxxb bands are ~100bp whilst VEGF 4/8 primers produce several bands between 100bp and 500bp due to alternative splicing.

Figure 3: Composition of gels to show relative levels of VEGF 4/8, VEGFxxxb and Sprk1 in AML samples. GAPDH was used to determine the amount of cDNA in samples to allow interpretation of the expression of the genes of interest. In the majority of cases, the intensity of the bands are proportional to the loading control (G6PDH), however, eg, 1454 shows a lower expression of VEGFxxxb than expected, 896 looks to correlate to this pattern but not as strongly.

Figure 4: The samples were checked for baseline cDNA levels using the same methods as previously. They were then PCR'd with oligos for the 5' and 3' terminals as well as for exon 9 splicing. Once the samples had been run they were analysed for candidate samples to be sent for sequencing by GATC technologies. Samples L254 and R84 were chosen as positive and negative controls for exon 9 splicing. Samples 810, 816 and 254 were chosen as initial samples for C terminal sequencing. White spaces indicate where the bands were not run due to lack of sample material.

Figure 5: Samples were run through MEGAS to visualise the sequence alignment to make it easier to locate the wild type KTS coding sequence. The sequence is shown below the MEGAS window with the KTS sequence being highlighted in blue. Direct comparison allows us to prove that the samples were wild type as the KTS sequence was present. The GATC visualization shows the sequence and levels of bases from the sample.

Figure 6: NIGAS analysis of oligonucleotide primers to check that exon 9 had been spliced from the KTS sequence. The highlighted region show the spliced sequence that confirms the exclusion of exon 9 from the WT1 coding sequence. After checking that exon 9 had been spliced each sample was visualised through the GATC viewer and compared to the expected sequence to look for any mutation, only one sample (1706) showed variation, the screenshot is shown below and suggests a base change on one of the replicating DNA strands. (Figure 7.)